$61.51
1.77% yesterday
Nasdaq, Apr 28, 10:15 pm CET
ISIN
US8036071004
Symbol
SRPT

Sarepta Therapeutics, Inc. Stock price

$61.51
-8.90 12.64% 1M
-68.75 52.78% 6M
-60.08 49.41% YTD
-67.29 52.24% 1Y
-12.65 17.06% 3Y
-58.18 48.61% 5Y
+48.45 370.98% 10Y
Nasdaq, Closing price Mon, Apr 28 2025
+1.07 1.77%
ISIN
US8036071004
Symbol
SRPT
Sector
Industry

Key metrics

Market capitalization $5.97b
Enterprise Value $5.96b
P/E (TTM) P/E ratio 25.81
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3.13
P/S ratio (TTM) P/S ratio 3.14
P/B ratio (TTM) P/B ratio 3.90
Revenue growth (TTM) Revenue growth 52.97%
Revenue (TTM) Revenue $1.90b
EBIT (operating result TTM) EBIT $218.08m
Free Cash Flow (TTM) Free Cash Flow $-342.74m
Cash position $1.35b
EPS (TTM) EPS $2.38
P/E forward 16.57
P/S forward 1.96
EV/Sales forward 1.96
Short interest 7.13%
Show more

Is Sarepta Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Sarepta Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

25 Analysts have issued a Sarepta Therapeutics, Inc. forecast:

21x Buy
84%
4x Hold
16%

Analyst Opinions

25 Analysts have issued a Sarepta Therapeutics, Inc. forecast:

Buy
84%
Hold
16%

Financial data from Sarepta Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
1,902 1,902
53% 53%
100%
- Direct Costs 357 357
83% 83%
19%
1,545 1,545
47% 47%
81%
- Selling and Administrative Expenses 495 495
20% 20%
26%
- Research and Development Expense 778 778
8% 8%
41%
272 272
230% 230%
14%
- Depreciation and Amortization 54 54
8% 8%
3%
EBIT (Operating Income) EBIT 218 218
181% 181%
11%
Net Profit 235 235
144% 144%
12%

In millions USD.

Don't miss a Thing! We will send you all news about Sarepta Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Sarepta Therapeutics, Inc. Stock News

Neutral
Business Wire
7 days ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2025 financial results after the Nasdaq Global Market closes on Tuesday, May 6, 2025. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its first quarter 2025 financial results. The event will be webc...
Positive
Investors Business Daily
8 days ago
Shares of gene therapy companies — including Sarepta Therapeutics — got a lift Monday after FDA's Marty Makary laid out his plans.
Neutral
Business Wire
14 days ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today shared updates from its clinical programs focused on limb-girdle muscular dystrophy (LGMD) subtypes 2C/R5, 2D/R3, and 2E/R4. SRP-9005 for LGMD type 2C/R5: Following input from the U.S. Food and Drug Administration (FDA), Office of Therapeutic Products (O...
More Sarepta Therapeutics, Inc. News

Company Profile

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Head office United States
CEO Douglas Ingram
Employees 1,372
Founded 1980
Website www.sarepta.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today